- Home
- NI vs GMAB Comparison
NI vs GMAB Comparison
Compare NI & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NI
- GMAB
- Stock Information
- Founded
- NI 1912
- GMAB 1999
- Country
- NI United States
- GMAB Denmark
- Employees
- NI N/A
- GMAB N/A
- Industry
- NI Power Generation
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- NI Utilities
- GMAB Health Care
- Exchange
- NI Nasdaq
- GMAB Nasdaq
- Market Cap
- NI 17.6B
- GMAB 15.0B
- IPO Year
- NI N/A
- GMAB N/A
- Fundamental
- Price
- NI $38.01
- GMAB $19.45
- Analyst Decision
- NI Strong Buy
- GMAB Buy
- Analyst Count
- NI 8
- GMAB 8
- Target Price
- NI $37.50
- GMAB $43.00
- AVG Volume (30 Days)
- NI 3.6M
- GMAB 1.6M
- Earning Date
- NI 02-19-2025
- GMAB 02-12-2025
- Dividend Yield
- NI 2.99%
- GMAB N/A
- EPS Growth
- NI 9.78
- GMAB 14.35
- EPS
- NI 1.64
- GMAB 10.80
- Revenue
- NI $5,289,300,000.00
- GMAB $2,967,926,227.00
- Revenue This Year
- NI $12.31
- GMAB $32.08
- Revenue Next Year
- NI $4.21
- GMAB $17.51
- P/E Ratio
- NI $22.78
- GMAB $17.44
- Revenue Growth
- NI N/A
- GMAB 17.75
- 52 Week Low
- NI $24.80
- GMAB $19.00
- 52 Week High
- NI $38.83
- GMAB $31.88
- Technical
- Relative Strength Index (RSI)
- NI 55.87
- GMAB 37.82
- Support Level
- NI $36.55
- GMAB $19.00
- Resistance Level
- NI $37.77
- GMAB $19.43
- Average True Range (ATR)
- NI 0.77
- GMAB 0.41
- MACD
- NI 0.02
- GMAB -0.19
- Stochastic Oscillator
- NI 61.00
- GMAB 11.58
About NI NiSource Inc
NiSource is one of the nation's largest natural gas distribution companies with approximately 3.2 million customers in Indiana, Kentucky, Maryland, Ohio, Pennsylvania, and Virginia. NiSource's electric utility transmits and distributes electricity in northern Indiana to about 500,000 customers. The regulated electric utility also owns more than 3,000 megawatts of generation capacity, including coal, natural gas, and renewable energy.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.